New drugs for chronic myelogenous leukemia (Q37843769)

24 August 2017

1 reference

title

New drugs for chronic myelogenous leukemia (English)

1 reference

24 August 2017

1 reference

Fabio P S Santos

1

1 reference

24 August 2017

Alfonso Quintás-Cardama

series ordinal

2

1 reference

24 August 2017

publication date

1 June 2011

1 reference

Current hematologic malignancy reports

24 August 2017

published in

1 reference

24 August 2017

volume

6

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

96-103

1 reference

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

The cellular geography of aurora kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-011-0079-9

Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts

21 January 2018

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells

1 reference

12 December 2020

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

1 reference

12 December 2020

10.1007/S11899-011-0079-9

Identifiers

DOI

1 reference

24 August 2017

1 reference